<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Clinical Microbiology</title>
    <link>http://repub.eur.nl/res/org/9821/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>The organellar genome and metabolic potential of the hydrogen- producing mitochondrion of Nyctotherus ovalis (Article)</title>
      <link>http://repub.eur.nl/res/pub/24021/</link>
      <pubDate>2011-08-01T00:00:00Z</pubDate>
      <description>
        
        Abstract
It is generally accepted that hydrogenosomes (hydrogen-producing organelles) evolved from a mitochondrial ancestor. However, until recently, only indirect evidence for this hypothesis was available. Here, we present the almost complete genome of the hydrogen-producing mitochondrion of the anaerobic ciliate Nyctotherus ovalis and show that, except for the notable absence of genes encoding electron transport chain components of Complexes III, IV, and V, it has a gene content similar to the mitochondrial genomes of aerobic ciliates. Analysis of the genome of the hydrogen-producing mitochondrion, in combination with that of more than 9,000 genomic DNA and cDNA sequences, allows a preliminary reconstruction of the organellar metabolism. The sequence data indicate that N. ovalis possesses hydrogen-producing
mitochondria that have a truncated, two step (Complex I and II) electron transport chai that uses fumarate as electron acceptor. In addition, components of an extensive protein network for the metabolism of amino acids, defense against oxidative stress, mitochondrial protein synthesis, mitochondrial protein import and processing, and transport of metabolites across the mitochondrial membrane were identified. Genes for MPV17 and ACN9, two hypothetical proteins
linked to mitochondrial disease in humans, were also found. The inferred metabolism is remarkably similar to the organellar metabolism of the phylogenetically distant anaerobic Stramenopile Blastocystis. Notably, the Blastocystis organelle and that of the related flagellate Proteromonas lacertae also lack genes encoding components of Complexes III, IV, and V. Thus, our data show that the hydrogenosomes of N. ovalis are highly specialized hydrogen-producing
mitochondria.
      </description>
      <author>Hackstein, J.H.P</author> <author>Burgtorf, C.</author> <author>Tielens, A.G.M.</author> <author>Dutilh, B.E.</author> <author>Duarte, I.</author> <author>Staay, G. W. M. van der</author> <author>Graaf, R.M. de</author> <author>Kuiper, J.W.P.</author> <author>Huynen, M.</author> <author>Alen, T.A. van</author> <author>Ricard, G</author>
    </item> <item>
      <title>High incidence of guillain-barré syndrome in children, Bangladesh (Article)</title>
      <link>http://repub.eur.nl/res/pub/26690/</link>
      <pubDate>2011-07-01T00:00:00Z</pubDate>
      <description>
        
        
      </description>
      <author>Islam, Z.</author> <author>Jacobs, B.C.</author> <author>Mohammad, Q.D.</author> <author>Diorditsa, S.</author> <author>Endtz, H.P.</author>
    </item> <item>
      <title>Chlamydia trachomatis infection during pregnancy associated with preterm delivery: A population-based prospective cohort study (Article)</title>
      <link>http://repub.eur.nl/res/pub/25130/</link>
      <pubDate>2011-06-01T00:00:00Z</pubDate>
      <description>
        
        Chlamydia trachomatis infection is the most prevalent bacterial sexually transmitted infection and may influence pregnancy outcome. This study was conducted to assess the effect of chlamydial infection during pregnancy on premature delivery and birthweight. Pregnant women attending a participating midwifery practice or antenatal clinic between February 2003 and January 2005 were eligible for the study. From 4,055 women self-administered questionnaires and urine samples, tested by PCR, were analysed for C. trachomatis infection. Pregnancy outcomes were obtained from midwives and hospital registries. Gestational ages and birthweights were analysed for 3,913 newborns. The C. trachomatis prevalence was 3.9%, but varied by age and socio-economic background. Chlamydial infection was, after adjustment for potential confounders, associated with preterm delivery before 32 weeks (OR 4.35 [95% CI 1.3, 15.2]) and 35 weeks gestation (OR 2.66 [95% CI 1.1, 6.5]), but not with low birthweight. Of all deliveries before 32 weeks and 35 weeks gestation 14.9% [95% CI 4.5, 39.5] and 7.4% [95% CI 2.5, 20.1] was attributable to C. trachomatis infection. Chlamydia trachomatis infection contributes significantly to early premature delivery and should be considered a public health problem, especially in young women and others at increased risk of C. trachomatis infection. 
      </description>
      <author>Rours, G.I.J.G.</author> <author>Dujits, L.</author> <author>Willemse, H.F.</author> <author>Zwaan, E.A. van der</author> <author>Verkooijen, R.P.</author> <author>Verbrugh, H.A.</author> <author>Moll, H.A.</author> <author>Arends, L.R.</author> <author>Groot, R. de</author> <author>Jaddoe, V.W.V.</author> <author>Hofman, A.</author> <author>Steegers-Theunissen, R.P.M.</author> <author>Mackenbach, J.P.</author> <author>Ott, A.</author>
    </item> <item>
      <title>First outbreak of VIM-2 metallo-β-lactamase-producing Pseudomonas aeruginosa in the Netherlands: Microbiology, epidemiology and clinical outcomes (Article)</title>
      <link>http://repub.eur.nl/res/pub/25704/</link>
      <pubDate>2011-06-01T00:00:00Z</pubDate>
      <description>
        
        This study was designed to investigate the prevalence and characteristics of metallo-β-lactamase (MBL)-producing Pseudomonas aeruginosa in a tertiary care centre in The Netherlands, a country that is considered to have a low prevalence of antibiotic-resistant bacteria. Imipenem-resistant P. aeruginosa isolates cultured from clinical specimens during 2008-2009 were analysed phenotypically and molecularly by polymerase chain reaction (PCR) with sequencing. Genotyping was performed by multiple-locus variable-number tandem repeat (VNTR) analysis (MLVA). Clinical information was obtained by electronic chart review for all patients infected or colonised with an imipenem-resistant P. aeruginosa isolate that was included in the study. In total, 106 imipenem-resistant P. aeruginosa isolates were included. The blaVIM-2gene was detected in 35/106 isolates (33%) and was associated with integrons. Compared with non-MBL-producing imipenem-resistant P. aeruginosa, VIM-2 MBL-producing isolates showed higher rates of multidrug resistance. Patients with VIM-2 MBL-producing isolates were more likely to be admitted to the Intensive Care Unit (ICU) and had a higher risk of invasive infection, including development of bacteraemia. MLVA identified two separate VIM-2 MBL-producing clones, responsible for outbreaks in the ICU but also affecting 10 other departments. This is the first reported outbreak of VIM-2 MBL-producing P. aeruginosa in The Netherlands. Once introduced, VIM-2 MBL-producing P. aeruginosa cause significant infections and are easily spread within the hospital setting. 
      </description>
      <author>Bij, A.K. van der</author> <author>Van Mansfeld, R.</author> <author>Peirano, G.</author> <author>Goessens, W.H.F.</author> <author>Severin, J.A.</author> <author>Pitout, J.D.D.</author> <author>Willems, R.J.L.</author> <author>Westreenen, M. van</author>
    </item> <item>
      <title>Phenotypic, genotypic, and antibiotic sensitivity patterns of strains isolated from the cholera epidemic in Zimbabwe (Article)</title>
      <link>http://repub.eur.nl/res/pub/26248/</link>
      <pubDate>2011-06-01T00:00:00Z</pubDate>
      <description>
        
        This paper details the phenotypic, genotypic, and antibiotic sensitivity patterns of 88 Vibrio cholerae strains from Zimbabwe. Of the 88 strains, 83 were classified as "altered El Tor" and 5 as "hybrid El Tor" strains. All of the strains were susceptible to tetracycline, doxycycline, ciprofloxacin, and azithromycin by disc diffusion, but susceptibility to tetracycline and azithromycin diminished when observed using the MIC method. Copyright 
      </description>
      <author>Islam, M.S.</author> <author>Mahmud, Z.H.</author> <author>Ahmed, S.</author> <author>Iqbal, A.</author> <author>Chitsatso, O.</author> <author>Mudzori, J.</author> <author>Patel, S.</author> <author>Midzi, S.M.</author> <author>Charimari, L.</author> <author>Endtz, H.P.</author> <author>Cravioto, A.</author> <author>Ansaruzzaman, M.</author> <author>Faruque, S.M.</author> <author>Talukder, K.A.</author> <author>Qadri, F.</author> <author>Alam, M.</author> <author>Bardhan, P.K.</author> <author>Mazumder, R.N.</author> <author>Khan, A.I.</author>
    </item> <item>
      <title>Selective depletion of neuropathy-related antibodies from human serum by monolithic affinity columns containing ganglioside mimics (Article)</title>
      <link>http://repub.eur.nl/res/pub/26263/</link>
      <pubDate>2011-05-26T00:00:00Z</pubDate>
      <description>
        
        Monolithic columns containing ganglioside GM2 and GM3 mimics were prepared for selective removal of serum anti-ganglioside antibodies from patients with acute and chronic immune-mediated neuropathies. ELISA results demonstrated that anti-GM2 IgM antibodies in human sera and a mouse monoclonal anti-GM2 antibody were specifically and selectively adsorbed by monolithic GM2 mimic columns and not by blank monolithic columns or monolithic GM3 mimic columns. In control studies, serum antibodies against the ganglioside GQ1b from another neuropathy patient were not depleted by monolithic GM2 mimic columns. Fluorescence microscopy with FITC-conjugated anti-human immunoglobulin antibodies showed that the immobilized ganglioside mimics were evenly distributed along the column. The columns were able to capture ?95% of the anti-GM2 antibodies of patients after only 2 min of incubation. A monolithic column of 4.4 μL can deplete 28.2 μL of undiluted serum. These columns are potential diagnostic and therapeutic tools for neuropathies related to anti-ganglioside antibodies. 
      </description>
      <author>Tetala, K.K.R.</author> <author>Heikema, A.P.</author> <author>Jacobs, B.C.</author> <author>Beek, T.A. van</author> <author>Pukin, A.V.</author> <author>Weijers, C.A.G.M.</author> <author>Tio-Gillen, A.P.</author> <author>Gilbert, M.</author> <author>Endtz, H.P.</author> <author>Belkum, A.F. van</author> <author>Zuilhof, H.</author> <author>Visser, G.M.</author>
    </item> <item>
      <title>Chlamydia trachomatis and placental inflammation in early preterm delivery (Article)</title>
      <link>http://repub.eur.nl/res/pub/25491/</link>
      <pubDate>2011-05-01T00:00:00Z</pubDate>
      <description>
        
        Chlamydia trachomatis may infect the placenta and subsequently lead to preterm delivery. Our aim was to evaluate the relationship between the presence of Chlamydia trachomatis and signs of placental inflammation in women who delivered at 32 weeks gestation or less. Setting: placental histology and clinical data were prospectively obtained from 304 women and newborns at the Erasmus MC-Sophia, Rotterdam, the Netherlands. C. trachomatis testing of placentas was done retrospectively using PCR. C. trachomatis was detected in 76 (25%) placentas. Histological evidence of placental inflammation was present in 123 (40%) placentas: in 41/76 (54%) placentas with C. trachomatis versus 82/228 (36%) placentas without C. trachomatis infection (OR 2.1, 95% CI 1.2-3.5). C. trachomatis infection correlated with the progression (P = 0.009) and intensity (P = 0.007) of materno-fetal placental inflammation. C. trachomatis DNA was frequently detected in the placenta of women with early preterm delivery, and was associated with histopathological signs of placental inflammation. 
      </description>
      <author>Rours, G.I.J.G.</author> <author>Krijger, R.R. de</author> <author>Ott, A.</author> <author>Willemse, H.F.</author> <author>Groot, R. de</author> <author>Zimmermann, L.J.I.</author> <author>Kornelisse, R.F.</author> <author>Verbrugh, H.A.</author> <author>Verkooijen, R.P.</author>
    </item> <item>
      <title>Antibody responses in furunculosis patients vaccinated with autologous formalin-killed Staphylococcus aureus (Article)</title>
      <link>http://repub.eur.nl/res/pub/25131/</link>
      <pubDate>2011-04-21T00:00:00Z</pubDate>
      <description>
        
        Autologous vaccines (short: autovaccines) have been used since the beginning of the 20th century to treat chronic staphylococcal infections, but their mechanisms of action are still obscure. This prospective pilot study involved four patients with furunculosis who were vaccinated with autologous formalin-killed Staphylococcus aureus cells. Vaccines were individually prepared from the infecting S. aureus strain and repeatedly injected subcutaneously in increasing doses over several months. We characterized the virulence gene repertoire and spa genotype of the infecting and colonising S. aureus strains. Serum antibody responses to secreted and surface-bound bacterial antigens were determined by two-dimensional immunoblotting and flow-cytometry based assays (Luminex®). All patients reported clinical improvement. Molecular characterization showed that all strains isolated from one patient over time belonged to the same S. aureus clone. Already before treatment, there was robust antibody binding to a broad range of staphylococcal antigens. Autovaccination moderately boosted the IgG response to extracellular antigens in two patients, while the antibody response of the other two patients was not affected. Similarly, vaccination moderately enhanced the antibody response against some staphylococcal surface proteins, e.g. ClfA, ClfB, SdrD and SdrE. In summary, autovaccination only slightly boosted the pre-existing serum antibody response, predominantly to bacterial surface antigens. 
      </description>
      <author>Holtfreter, S.</author> <author>Jursa-Kulesza, J.</author> <author>Völker, U.</author> <author>Giedrys-Kalemba, S.T.</author> <author>Bröker, B.M.</author> <author>Masiuk, H.</author> <author>Verkaik, N.J.</author> <author>Vogel, C.P. de</author> <author>Kolata, J.</author> <author>Nowosiad, M.</author> <author>Steil, L.</author> <author>Wamel, W.J.B. van</author> <author>Belkum, A.F. van</author>
    </item> <item>
      <title>A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients (Article)</title>
      <link>http://repub.eur.nl/res/pub/25497/</link>
      <pubDate>2011-04-01T00:00:00Z</pubDate>
      <description>
        
        Background. In human immunodeficiency virus (HIV)-infected patients, the immunogenicity of hepatitis B vaccines is impaired. The primary and secondary aims of our study were to investigate the effectiveness and compliance of 2 different vaccination regimen in an HIV-infected population. Methods. A noninferiority trial with a 10% response margin was designed. Included were patients ≥18 years old, with negative HBsAg/anti-HBc serology, and not previously vaccinated against hepatitis B. Patients were stratified according to CD4+cell count: &lt;200, 200-500, &gt;500. Participants received 10 μg HBvaxPRO intramuscularly according to a 0-1-3 week schedule or the standard 0-4-24 week schedule. Anti-HBs levels were measured at week 28, considered protective ≥10 IU/L. Results. Modified intention to treat analysis in 761 patients was performed. Overall response difference was 50%(standard arm) versus 38.7% (accelerated arm) =11.3% (95% confidence interval [CI], [4.3, 18.3]), close to the 10% response margin. In CD4+cell count group 200-500 cells/mm3, the response difference was 20.8% (95% CI [10.9, 30.7]). However, the response difference in CD4+cell count group .500 cells/mm3 was -1.8% (95% CI [-13.4,19.7]). Compliance was significantly superior with the accelerated schedule, 91.8% versus 82.7% (P ≤ .001). Conclusion. In HIV-infected patients, compliance with an accelerated hepatitis B vaccination schedule is significantly better. The efficacy of an accelerated schedule proved to be non-inferior in CD4+cell count group &gt;500 cells/mm3. 
      </description>
      <author>Vries-Sluijs, T.E.M.S. de</author> <author>Hansen, B.E.</author> <author>Ende, M.E. van der</author> <author>Man, R.A. de</author> <author>Doornum, G.J.J. van</author> <author>Kauffmann, R.H.</author> <author>Leyten, E.M.S.</author> <author>Mudrikova, T.</author> <author>Brinkman, K.</author> <author>Hollander, J.G. den</author> <author>Kroon, F.P.</author> <author>Janssen, H.L.A.</author>
    </item> <item>
      <title>Development of a multiplexed bead-based immunoassay for the simultaneous detection of antibodies to 17 pneumococcal proteins (Letter To Editor)</title>
      <link>http://repub.eur.nl/res/pub/25521/</link>
      <pubDate>2011-04-01T00:00:00Z</pubDate>
      <description>
        
        Presently, several pneumococcal proteins are being evaluated as potential vaccine candidates. Here, we gather novel insights in the immunogenicity of PLY, PsaA, PspA, PspC, NanA, Hyl, PpmA, SlrA, Eno, IgA1-protease, PdBD, BVH-3, SP1003, SP1633, SP1651, SP0189 and SP0376. We developed a multiplex bead-based immunoassay (xMAP® Technology, Luminex Corporation) to simultaneously quantify antibodies against these 17 pneumococcal proteins in serum. The median fluorescence intensity (MFI) values obtained for human pooled serum with the multiplex assay were between 82% and 111% (median 94%) of those obtained with the singleplex assays. For IgG, the coefficient of variation (CV) in serum ranged from 2% to 9%, for IgA, the CV ranged from 3% to 14% and for IgM, the CV ranged from 11% to 15%. Using this immunoassay, we showed that anti-pneumococcal antibody levels exhibited extensive inter-individual variability in young children suffering from invasive pneumococcal disease. All proteins, including the proteins with, as yet, unknown function, were immunogenic. In conclusion, the multiplex Streptococcus pneumoniae immunoassay based on proteins is reproducible. This assay can be used to monitor anti-S. pneumoniae antibody responses in a material- and time-saving manner. 
      </description>
      <author>Shoma, S.</author> <author>Verkaik, N.J.</author> <author>Wamel, W.J.B. van</author> <author>Belkum, A.F. van</author> <author>Vogel, C.P. de</author> <author>Hermans, P.W.M.</author> <author>Selm, S. van</author> <author>Mitchell, T.J.</author> <author>Roosmalen, M.H. van</author> <author>Hossain, S.</author> <author>Rahman, M.</author> <author>Endtz, H.P.</author>
    </item> <item>
      <title>In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine (Article)</title>
      <link>http://repub.eur.nl/res/pub/25553/</link>
      <pubDate>2011-04-01T00:00:00Z</pubDate>
      <description>
        
        Presently, therapy of eumycetoma in Sudan is still based on surgery combined with prolonged ketoconazole therapy. This usually results in a poor clinical outcome. To determine if posaconazole and terbinafine could offer better therapeutic alternatives, the in vitro susceptibilities of 34 Madurella mycetomatis strains were determined. It appeared that posaconazole was highly active against M. mycetomatis but terbinafine was only moderately active. Since posaconazole has an excellent safety profile, it might provide an important alternative in mycetoma therapy. Copyright 
      </description>
      <author>Belkum, A.F. van</author> <author>Fahal, A.</author> <author>Sande, W.W.J. van de</author>
    </item> <item>
      <title>Immunologic functions as prognostic indicators in melanoma (Article)</title>
      <link>http://repub.eur.nl/res/pub/25860/</link>
      <pubDate>2011-04-01T00:00:00Z</pubDate>
      <description>
        
        Outcome in melanoma patients with advanced disease is poor and systemic treatment seems to benefit only a subset of patients. Predictive markers identifying these patients are currently not available. Early studies showed an association of immune-related side effects such as vitiligo and autoimmune thyroiditis with response to IL-2 or IFNα treatment. However, conflicting data have been reported as well, mentioning the effect of a higher rate of immune-related toxicities during prolonged administration of the drug in responders. The review discusses the prognostic significance of autoimmunity during various forms of immunotherapy and stresses the importance of correcting for guarantee-time bias. In addition, other immune-related factors which have been associated with melanoma prognosis such as, CRP, white blood cell count, absolute lymphocyte count and human leukocyte antigen will be reviewed as well. A better understanding of the immune system and the host-tumor interactions should ultimately lead to more effective treatment. A major challenge expected to be addressed in future is proving ways to uncouple tumor immunity from autoimmunity. 
      </description>
      <author>Bouwhuis, M.G.</author> <author>Hagen, T.L.M. ten</author> <author>Eggermont, A.M.M.</author>
    </item> <item>
      <title>Meticillin-resistant Staphylococcus aureus (MRSA): Screening and decolonisation (Article)</title>
      <link>http://repub.eur.nl/res/pub/23050/</link>
      <pubDate>2011-03-01T00:00:00Z</pubDate>
      <description>
        
        Meticillin-resistant Staphylococcus aureus (MRSA) infections are of increasing importance to clinicians, public health agencies and governments. Prevention and control strategies must address sources in healthcare settings, the community and livestock. This document presents the conclusions of a European Consensus Conference on the role of screening and decolonisation in the control of MRSA infection. The conference was held in Rome on 5-6 March 2010 and was organised jointly by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC). In an environment where MRSA is endemic, universal or targeted screening of patients to detect colonisation was considered to be an essential pillar of any MRSA control programme, along with the option of decolonising carriers dependent on relative risk of infection, either to self or others, in a specific setting. Staff screening may be useful but is problematic as it needs to distinguish between transient carriage and longer-term colonisation. The consequences of identification of MRSA-positive staff may have important effects on morale and the ability to maintain staffing levels. The role of environmental contamination in MRSA infection is unclear, but screening may be helpful as an audit of hygiene procedures. In all situations, screening procedures and decolonisation carry a significant cost burden, the clinical value of which requires careful evaluation. European initiatives designed to provide further information on the cost/benefit value of particular strategies in the control of infection, including those involving MRSA, are in progress.
      </description>
      <author>Cookson, B.</author> <author>Bonten, M.J.M.</author> <author>Mackenzie, F.M.</author> <author>Skov, R.</author> <author>Verbrugh, H.A.</author> <author>Tacconelli, E.</author>
    </item> <item>
      <title>Genome sequence of the zoonotic pathogen Chlamydophila psittaci (Article)</title>
      <link>http://repub.eur.nl/res/pub/23052/</link>
      <pubDate>2011-03-01T00:00:00Z</pubDate>
      <description>
        
        We present the first genome sequence of Chlamydophila psittaci, an intracellular pathogen of birds and a human zoonotic pathogen. A comparison with previously sequenced Chlamydophila genomes shows that, as in other chlamydiae, most of the genome diversity is restricted to the plasticity zone. The C. psittaci plasmid was also sequenced.
      </description>
      <author>Seth-Smith, H.M.B.</author> <author>Harris, S.R.</author> <author>Clarke, I.N.</author> <author>Thomson, N.R.</author> <author>Rance, R.</author> <author>West, A.P.</author> <author>Severin, J.A.</author> <author>Ossewaarde, J.M.</author> <author>Cutcliffe, L.T.</author> <author>Skilton, R.J.</author> <author>Marsh, P.</author> <author>Parkhill, J.</author>
    </item> <item>
      <title>Analysis of mechanisms involved in reduced susceptibility to ciprofloxacin in Salmonella enterica serotypes Typhi and Paratyphi A isolates from travellers to Southeast Asia (Article)</title>
      <link>http://repub.eur.nl/res/pub/23848/</link>
      <pubDate>2011-03-01T00:00:00Z</pubDate>
      <description>
        
        Owing to multidrug resistance, quinolones and third-generation cephalosporins are currently used as key antibiotics to combat Salmonella organisms. Therapy failure due to reduced ciprofloxacin susceptibility has been reported in endemic areas, but also in imported disease. Different bacterial resistance mechanisms may result in reduced ciprofloxacin susceptibility. In this study, the presence and expression of different resistance mechanisms resulting in reduced minimum inhibitory concentrations (MICs) for ciprofloxacin were evaluated in 23 blood-culture-derived Salmonella enterica serotypes Typhi and Paratyphi A organisms from ill-returned travellers to Asia. The presence of mutations in the quinolone resistance-determining region (QRDR) of the gyrA gene as well as an activated efflux pump and plasmid-mediated quinolone resistance genes was determined. Resistance selection during therapy and the clonal relatedness of all isolates were established. Efflux pump inhibition did not appear to affect the MICs of ciprofloxacin and activity of the efflux pump appeared to be specific for nalidixic acid. Repeated exposure of the isolates to ciprofloxacin did not result in a significant increase in the MICs for ciprofloxacin. Repetitive sequence-based polymerase chain reaction (rep-PCR) profiles identified five different genotypes, but no correlation with resistance was observed. However, a significant relation was found with geographic region; reduced ciprofloxacin susceptibility was only found in travellers returning from India and Pakistan. All isolates with reduced ciprofloxacin susceptibility had a mutation at position 83 in the QRDR region of the gyrA gene. Plasmid-mediated quinolone resistance was not found. These findings confirm that the reduced ciprofloxacin MIC in S. Typhi and S. Paratyphi A is solely due to an amino acid substitution in the QRDR 'cluster' of the gyrA gene. 
      </description>
      <author>Hassing, R.J.</author> <author>Menezes, G.A.</author> <author>Pelt, W. van</author> <author>Petit, P.L.</author> <author>Genderen, P.J.J.  van</author> <author>Goessens, W.H.F.</author>
    </item> <item>
      <title>Autoimmunity and treatment outcome in melanoma (Article)</title>
      <link>http://repub.eur.nl/res/pub/23852/</link>
      <pubDate>2011-03-01T00:00:00Z</pubDate>
      <description>
        
        Purpose of review: Only a subset of melanoma patients with advanced disease seems to benefit from immunotherapy. Predictive markers identifying these patients are unfortunately not available. Whether immune-related side effects could serve as predictors for treatment response or just resemble unwanted side effects from immunotherapy will be outlined in this review. Recent findings: Early studies suggested an association of immune-related side effects such as vitiligo and autoimmune thyroiditis with response in patients receiving IL-2 or IFNÎ±. However, conflicting data have been reported as well, mentioning the effect of a higher rate of immune-related toxicities during prolonged administration of the drug in responders/survivors. This type of bias is also known as guarantee-time bias. Recently, a clearly significant and clinically relevant prolongation of survival was demonstrated in patients with metastatic melanoma treated with ipilimumab. Immune-related adverse events were associated with response to ipilimumab, however, at the cost of considerable toxicity. Summary: Evidence for an association of immune-related toxicities and response in patients receiving IL-2 or IFNÎ± is weak, considering guarantee-time bias. On the contrary, this association for patients receiving anti-cytotoxic T-lymphocyte antigen-4 therapy (ipilimumab) appears much stronger. Importantly, can we uncouple tumor immunity from autoimmunity in order to optimize immunotherapy in melanoma? 
      </description>
      <author>Bouwhuis, M.G.</author> <author>Hagen, T.L.M. ten</author> <author>Suciu, S.</author> <author>Eggermont, A.M.M.</author>
    </item> <item>
      <title>Individual accumulation of heterogeneous risks explains perinatal inequalities within deprived neighbourhoods (Article)</title>
      <link>http://repub.eur.nl/res/pub/26523/</link>
      <pubDate>2011-02-01T00:00:00Z</pubDate>
      <description>
        
        Dutch' figures on perinatal mortality and morbidity are poor compared to EU-standards. Considerable within-country differences have been reported too, with decreased perinatal health in deprived urban areas. We investigated associations between perinatal risk factors and adverse perinatal outcomes in 7,359 pregnant women participating in population-based prospective cohort study, to establish the independent role, if any, for living within a deprived urban neighbourhood. Main outcome measures included perinatal death, intrauterine growth restriction (IUGR), prematurity, congenital malformations, Apgar at 5 min &lt; 7, and pre-eclampsia. Information regarding individual risk factors was obtained from questionnaires, physical examinations, ultrasounds, biological samples, and medical records. The dichotomous Dutch deprivation indicator was additionally used to test for unexplained deprived urban area effects. Pregnancies from a deprived neighbourhood had an increased risk for perinatal death (RR 1.8, 95% CI [1.1; 3.1]). IUGR, prematurity, Apgar at 5 min &lt; 7, and pre-eclampsia also showed higher prevalences (P &lt; 0.05). Residing within a deprived neighbourhood was associated with increased prevalence of all measured risk factors. Regression analysis showed that the observed neighbourhood related differences in perinatal outcomes could be attributed to the increased risk factor prevalence only, without a separated role for living within a deprived neighbourhood. Women from a deprived neighbourhood had significantly more 'possibly avoidable' risk factors. To conclude, women from a socioeconomically deprived neighbourhood are at an increased risk for adverse pregnancy outcomes. Differences regarding possibly avoidable risk factors imply that preventive strategies may prove effective. 
      </description>
      <author>Timmermans, S.</author> <author>Bonsel, G.J.</author> <author>Looman, C.W.N.</author> <author>Jaddoe, V.W.V.</author> <author>Steegers-Theunissen, R.P.M.</author> <author>Mackenbach, J.P.</author> <author>Steyerberg, E.W.</author> <author>Raat, H.</author> <author>Verbrugh, H.A.</author> <author>Tiemeier, H.</author> <author>Hofman, A.</author> <author>Birnie, E.</author>
    </item> <item>
      <title>Risk factors for otitis media in children with special emphasis on the role of colonization with bacterial airway pathogens: The Generation R study (Article)</title>
      <link>http://repub.eur.nl/res/pub/23761/</link>
      <pubDate>2011-01-01T00:00:00Z</pubDate>
      <description>
        
        Acute otitis media is the most frequent diagnosis in children visiting physicians' offices. Risk factors for otitis media have been widely studied. Yet, the correlation between bacterial carriage and the development of otitis media is not entirely clear. Our aim was to study in a population-based prospective cohort the risk factors for otitis media in the second year of life with special emphasis on the role of colonization with Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. The study was embedded in the Generation R Study. Data on risk factors and doctor-diagnosed otitis media were obtained by midwives, hospital registries and postal questionnaires in the whole cohort (n = 7,295). Nasopharyngeal swabs were obtained at the age of 1.5, 6 and 14 months in the focus cohort (n = 1,079). Of these children, 2,515 (47.2%) suffered at least one period of otitis media in their second year of life. The occurrence of otitis media during the follow-up period in the first 6 months of life and between 6 and 12 months of age was associated with the risk of otitis media in the second year of life (aOR, 1.83 95% CI 1.24-2.71 and aOR 2.72, 95% CI 2.18-3.38, respectively). Having siblings was associated with an increased risk for otitis media in the second year of life (aOR 1.42, 95% CI 1.13-1.79). No associations were found between bacterial carriage in the first year of life and otitis media in the second year of life. In our study, otitis media in the first year of life is an independent risk factor for otitis media in the second year of life. Surprisingly, bacterial carriage in the first year of life did not add to this risk. Moreover, no association was observed between bacterial carriage in the first year of life and otitis in the second year of life.
      </description>
      <author>Labout, J.A.M.</author> <author>Dujits, L.</author> <author>Lebon, A.</author> <author>Groot, R. de</author> <author>Hofman, A.</author> <author>Jaddoe, V.W.V.</author> <author>Verbrugh, H.A.</author> <author>Hermans, P.W.M.</author> <author>Moll, H.A.</author>
    </item> <item>
      <title>Differential expression and prognostic value of HMGA1 in pancreatic head and periampullary cancer (Article)</title>
      <link>http://repub.eur.nl/res/pub/21004/</link>
      <pubDate>2010-12-01T00:00:00Z</pubDate>
      <description>
        
        The high mortality rate and minimal progress made in the treatment of pancreatic cancer over the last few decades, warrant an alternative approach. Treatment protocols should be individualised to the patient guided by prognostic markers. A particularly interesting target would be the architectural transcription factor high mobility group A1 (HMGA1), that is low or undetectable in normal tissue, induced during neoplastic transformation and consequently often exceptionally high in cancer. The aim of the current study was therefore to determine the differential expression of HMGA1 in pancreatic head and periampullary cancer and investigate its relation with outcome. HMGA1 expression was determined by immunohistochemistry on original paraffin embedded tissue from 99 pancreatic head- and 112 periampullary cancers (with R0). Expression was investigated for associations with recurrence free (RFS), cancer specific (CSS) and overall survival (OS) and conventional prognostic factors. HMGA1 was expressed in 47% and 26% of pancreatic head- and periampullary cancer, respectively and associated with poor RFS, CSS and OS in periampullary cancer. CSS 5 years following surgery was 25% and 44% for patients with tumours which were positive or negative for HMGA1 protein, respectively. HMGA1 expression was not associated with survival in pancreatic head cancer. In conclusion HMGA1 was identified as an independent prognostic marker predicting poor outcome in periampullary cancer. Although expressed to a higher extent as compared to periampullary cancer, HMGA1 was not associated with survival in pancreatic head cancer.
      </description>
      <author>Zee, J. van der</author> <author>Hagen, T.L.M. ten</author> <author>Hop, W.C.J.</author> <author>Dekken, H. van</author> <author>Dicheva, B.M.</author> <author>Seynhaeve, A.L.B.</author> <author>Koning, G.A.</author> <author>Eggermont, A.M.M.</author> <author>Eijck, C.H.J. van</author>
    </item> <item>
      <title>Molecular characterization of antimicrobial resistance in non-typhoidal salmonellae associated with systemic manifestations from India (Article)</title>
      <link>http://repub.eur.nl/res/pub/21959/</link>
      <pubDate>2010-12-01T00:00:00Z</pubDate>
      <description>
        
        Extended-spectrum cephalosporins and fluoroquinolones are essential antimicrobials for treating invasive salmonellosis, although emerging resistance to these antimicrobials is of growing concern, especially in India. Therefore, a study was conducted to characterize the antimicrobial susceptibility phenotypes, types of extended-spectrum β-lactamase (ESBL) gene plasmids and serological relationships of 21 non-typhoidal Salmonella isolates from patients who attended three different hospitals in India from 2006 to 2008. The isolates were cultured from stool, blood and cerebrospinal fluid samples obtained from patients presenting with diarrhoea and accompanying systemic manifestations such as fever, vomiting and meningism. Non-typhoidal Salmonella isolates were investigated using serotyping and antimicrobial susceptibility testing. PCR screening was also performed to detect the β-lactamase, qnr and aac(6′)-Ib-cr genes and class 1 integrons. Sequencing for quinolone resistance mutations and plasmid replicon typing were also performed. An antimicrobial resistance microarray was used for preliminary screening and identification of blaTEM and blaSHV  genes, and phenotypic testing for the presence of efflux pumps was also performed. Ten out of 21 isolates (48 %) possessed the extended-spectrum cephalosporin resistance phenotype, with PCR amplification and sequencing revealing that isolates possessed TEM-1, SHV-12, DHA-1, OXA-1-like and CTX-M-15 ESBL genes. FII s plasmid replicons were detected in seven isolates (33 %). The involvement of efflux pumps was detected in four isolates (19 %) resistant to ciprofloxacin. It was concluded that SHV-12-carrying Salmonella serotype Agona may play an important role in ESBL-mediated resistance in non-typhoidal salmonellae in India. The very high percentage (48 %) of ESBL-producing non-typhoidal salmonellae isolated from these patients represents a real and immediate challenge to the effective antimicrobial therapy of Salmonella infections associated with systemic manifestations. Continued surveillance for the presence of ESBL-producing (non-typhoidal) salmonellae in India is essential.
      </description>
      <author>Menezes, G.A.</author> <author>Khan, M.A.</author> <author>Harish, B.N.</author> <author>Parija, S.C.</author> <author>Goessens, W.H.F.</author> <author>Vidyalakshmi, K.</author> <author>Baliga, S.</author> <author>Hays, J.P.</author>
    </item>
  </channel>
</rss>